Wedbush reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report published on Monday morning, TipRanks reports. They currently have a $17.00 target price on the biopharmaceutical company’s stock.

Several other research analysts also recently issued reports on LXRX. G.Research upgraded Lexicon Pharmaceuticals from a hold rating to a buy rating in a research report on Wednesday, September 11th. Zacks Investment Research cut Lexicon Pharmaceuticals from a buy rating to a hold rating in a report on Saturday, November 16th. Gabelli raised Lexicon Pharmaceuticals from a hold rating to a buy rating and set a $3.00 price target for the company in a research report on Wednesday, September 11th. BidaskClub cut Lexicon Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, November 27th. Finally, ValuEngine upgraded Lexicon Pharmaceuticals from a strong sell rating to a sell rating in a research report on Wednesday, October 2nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $6.45.

Shares of LXRX stock opened at $3.16 on Monday. The business’s fifty day moving average price is $3.62 and its 200 day moving average price is $3.90. Lexicon Pharmaceuticals has a 1-year low of $1.13 and a 1-year high of $8.39. The firm has a market capitalization of $375.14 million, a PE ratio of -2.77 and a beta of 1.00. The company has a debt-to-equity ratio of 1.42, a current ratio of 8.11 and a quick ratio of 8.01.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.31 by $0.80. Lexicon Pharmaceuticals had a net margin of 49.78% and a return on equity of 2,372.40%. The firm had revenue of $294.45 million during the quarter, compared to the consensus estimate of $12.00 million. During the same period last year, the firm posted ($0.26) EPS. The firm’s revenue for the quarter was up 4124.5% on a year-over-year basis. Equities research analysts expect that Lexicon Pharmaceuticals will post 0.93 earnings per share for the current fiscal year.

In related news, Director Christopher J. Sobecki bought 99,249 shares of the stock in a transaction dated Friday, September 13th. The stock was acquired at an average price of $2.41 per share, for a total transaction of $239,190.09. Following the completion of the purchase, the director now owns 13,645 shares in the company, valued at $32,884.45. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Christopher J. Sobecki bought 25,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were bought at an average price of $2.55 per share, for a total transaction of $63,750.00. Following the completion of the acquisition, the director now owns 112,493 shares in the company, valued at approximately $286,857.15. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 178,749 shares of company stock valued at $474,560. 6.40% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in the company. Quantitative Systematic Strategies LLC boosted its holdings in Lexicon Pharmaceuticals by 67.2% in the second quarter. Quantitative Systematic Strategies LLC now owns 20,648 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 8,302 shares during the last quarter. Wedbush Securities Inc. lifted its position in shares of Lexicon Pharmaceuticals by 33.0% in the 2nd quarter. Wedbush Securities Inc. now owns 194,339 shares of the biopharmaceutical company’s stock worth $1,222,000 after buying an additional 48,182 shares during the last quarter. Swiss National Bank lifted its position in shares of Lexicon Pharmaceuticals by 18.3% in the 2nd quarter. Swiss National Bank now owns 88,614 shares of the biopharmaceutical company’s stock worth $557,000 after buying an additional 13,700 shares during the last quarter. GSA Capital Partners LLP boosted its holdings in shares of Lexicon Pharmaceuticals by 217.5% in the 2nd quarter. GSA Capital Partners LLP now owns 87,132 shares of the biopharmaceutical company’s stock valued at $548,000 after buying an additional 59,685 shares during the period. Finally, Trexquant Investment LP acquired a new position in shares of Lexicon Pharmaceuticals in the 2nd quarter valued at about $92,000. Institutional investors own 96.27% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Story: What is the S&P 500 Index?

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.